Vancouver, BC, Canada - July 9, 2012, Vancouver, BC, Canada - QLT Inc., a biotechnology company, announces that Robert Butchofsky, the company’s president and CEO, will be leaving the company, effective July 31, 2012.
Article continues below
]
Mr. Butchofsky was appointed as President and Chief Executive Officer and a Director of QLT in February 2006 following his earlier appointment as Acting Chief Executive Officer of QLT in September 2005. He joined QLT in 1998 as Associate Director, Ocular Marketing and was appointed Vice President, Marketing and Sales Planning in September 2001.
Mr. Butchofsky was promoted to Senior Vice President, Marketing and Sales Planning in early 2005, responsible for QLT's ongoing marketing of the pharmaceutical products, Visudyne and Eligard, including managing significant partnerships, as well as corporate strategy development and investor relations activities.
From June 1990 to August 1998, Mr. Butchofsky was employed at Allergan Inc., where he built an extensive background with ocular pharmaceutical products and Botox, including sales, health economics, worldwide medical marketing, and product management. Prior to joining Allergan Inc., Mr. Butchofsky spent several years managing clinical trials at the Institute for Biological Research and Development. Mr. Butchofsky also serves on the Board of Superna Life Sciences Inc., a privately-held pharmaceutical company.
Mr. Butchofsky has a Bachelor of Arts degree in Biology from the University of Texas and a Masters of Business Administration from Pepperdine University. Mr. Butchofsky will be leaving the company, but has graciously agreed to remain as CEO until July 31, 2012 or until the Board names a new CEO.
Mr. Sukhi Jagpal, QLT’s Controller, will assume the position of interim CFO succeeding Cameron Nelson, company's Senior Vice President, Finance and Chief Financial Officer.
Linda Lupini, QLT’s Senior Vice President, Human Resources and Organizational Development and Christopher Muller, Chief Commercial Officer of QLT Ophthalmics, Inc., will also be leaving the company.
The company also announce the appointment of Vince Anido to the company’s Board of Directors.
Dr. Anido is a highly respected ophthalmology industry veteran and leader. He assumes the directorship that was vacated. From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a Director of Ista Pharmaceuticals, a company recently acquired by Bausch & Lomb. ■